GENELUX CORPORATION APIC, Share-based Payment Arrangement, Increase for Cost Recognition
GENELUX CORPORATION (GNLX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.29 million for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-07.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2025-08-07
- GENELUX CORPORATION apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $1.29M, a 0.62% decline year-over-year.
- GENELUX CORPORATION apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-03-31 was $1.42M, a 4.43% decline year-over-year.
- GENELUX CORPORATION apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-12-31 was $1.43M, a 6.72% decline year-over-year.
- GENELUX CORPORATION apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-09-30 was $1.52M, a 195.34% increase year-over-year.
- GENELUX CORPORATION apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $5.74M, a 128.15% increase from fiscal 2023.
- GENELUX CORPORATION apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $2.52M, a 4.14% increase from fiscal 2022.
- GENELUX CORPORATION apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $2.42M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2025-06-30 | $1.29M 10-Q · filed 2025-08-07 | $2.71M derived: sum of 2 quarters · filed 2025-08-07 | $4.14M derived: sum of 3 quarters · filed 2025-08-07 | $5.66M derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | $1.42M 10-Q · filed 2025-08-07 | $2.85M derived: sum of 2 quarters · filed 2025-08-07 | $4.37M derived: sum of 3 quarters · filed 2025-08-07 | $5.67M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-12-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $2.95M derived: sum of 2 quarters · filed 2025-03-28 | $4.25M derived: sum of 3 quarters · filed 2025-08-07 | $5.74M 10-K · filed 2025-03-28 |
| 2024-09-30 | $1.52M 10-Q · filed 2024-11-14 | $2.82M derived: sum of 2 quarters · filed 2025-08-07 | $4.31M 10-Q · filed 2024-11-14 | $5.84M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-06-30 | $1.30M 10-Q · filed 2025-08-07 | $2.79M 10-Q · filed 2024-08-14 | $4.32M derived: sum of 3 quarters · filed 2025-08-07 | $4.83M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $1.49M 10-Q · filed 2025-08-07 | $3.02M derived: sum of 2 quarters · filed 2025-08-07 | $3.54M derived: sum of 3 quarters · filed 2025-08-07 | $3.78M derived: sum of 4 quarters · filed 2025-08-07 |
| 2023-12-31 | $1.53M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $2.05M derived: sum of 2 quarters · filed 2025-03-28 | $2.29M derived: sum of 3 quarters · filed 2025-03-28 | $2.52M 10-K · filed 2025-03-28 |
| 2023-09-30 | $515.00K 10-Q · filed 2024-11-14 | $755.00K derived: sum of 2 quarters · filed 2024-11-14 | $982.00K 10-Q · filed 2024-11-14 | $1.02M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $240.00K 10-Q · filed 2024-08-14 | $467.00K 10-Q · filed 2024-08-14 | $510.00K derived: sum of 3 quarters · filed 2024-08-14 | $2.21M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $227.00K 10-Q · filed 2024-05-09 | $270.00K derived: sum of 2 quarters · filed 2024-05-09 | $1.97M derived: sum of 3 quarters · filed 2024-05-09 | $2.27M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $43.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $1.75M derived: sum of 2 quarters · filed 2024-03-29 | $2.04M derived: sum of 3 quarters · filed 2024-03-29 | $2.42M 10-K · filed 2024-03-29 |
| 2022-09-30 | $1.70M 10-Q · filed 2023-11-14 | $2.00M derived: sum of 2 quarters · filed 2023-11-14 | $2.37M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $297.00K 10-Q · filed 2023-08-14 | $669.00K 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $372.00K 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |